New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Johnson & Johnson

JNJ

Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.

Revenue
+5.86%
EPS
−95.8%
Free cash flow
−21.4%
Total debt
−9.16%

Quarter to September 2026, against a year earlier

270.19 3.09 +1.16%
Market cap
$650.7B
P/E
40.5×
Fwd P/E FY26e
41.8×
Dividend yield
1.98%
F-score
3/9
ROIC
11.1%
Net debt / EBITDA
0.5×
Payout ratio
0.8×

Johnson & Johnson 10-Q filed Oct 21, 2026

Fiscal Q3 2026 · Period ended Sep 27, 2026 · Filed · accepted 4:18 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 23, 2026: 25 added · 29 removed · 35 modified; 27 with only figures updated; 6 moved without change

  1. Modified · Analysis of consolidated sales

    For the fiscal sixnine months of 2026, worldwide sales were $49.474.8 billion, a total increase of 8.27.4%, including an operational* increase of 6.0% as compared to 2025 fiscal sixnine months sales of $45.669.6 billion. Currency fluctuations had a positive impact of 2.21.4% for the fiscal sixnine months of 2026. In the fiscal sixnine months of 2026, acquisitions and divestitures had a net positive impact of 0.50.3%, on worldwide operational sales growth, primarily related to CAPLYTA. In the fiscal sixnine months of 2026, the negative impact of the STELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately 5.04.7%.